Cancer treatment company plans for public offeringJuly 25, 2019PetCure Oncology has engaged Boustead Securities for a Regulation D 506(c) offering.
SPONSORED CONTENTA brighter future for parvovirus patientsOur Canine Parvovirus Monoclonal Antibody helps puppies recover faster, and current users report reductions in clinic stress during parvo treatment.1,2 Find out why veterinary teams are embracing CPMA. + Read More